FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885293840> ?p ?o ?g. }

• W2885293840 endingPage "117822341879225" @default.
• W2885293840 startingPage "117822341879225" @default.
• W2885293840 abstract "Introduction: Multiple trials demonstrated that adding Bevacizumab to the standard neoadjuvant chemotherapy in HER-2 negative breast cancer increases pathological complete response. We conducted this meta-analysis to evaluate that effect on survival. Methods: We performed a systematic search for randomized trials measuring the effect of adding either neoadjuvant or adjuvant Bevacizumab to the standard chemotherapy on disease-free and overall survival in breast cancer surgical candidates. The Mantel-Haenszel method and random effect model were used to analyze the data. A total of 7 randomized controlled trials were included in the analysis with a mean follow-up of 45 months. Results: No statistically significant difference in overall survival was found after adding Bevacizumab to the standard chemotherapy in the overall study population, HR=0.9, 95% CI (90.72–1.13), estrogen/ progesterone positive subgroup, HR=0.99, 95% CI (0.72–1.35), or in triple negative breast cancer, HR=0.88, 95% CI (0.77–1.01). However, there was a small but significant improvement in disease-free survival in triple negative breast cancer with a HR of 0.88, 95% CI (0.78–0.98), but not in estrogen/ progesterone receptor positive tumors, HR=1.01, 95% CI (0.81–1.26). Conclusions: The addition of Bevacizumab along with the standard chemotherapy would not improve overall survival in breast cancer surgical candidates, however, due to a small but significant improvement on disease-free survival in triple negative breast cancer, that would not eliminate the possibility of a certain subgroup of the latter who might benefit from adding Bevacizumab." @default.
• W2885293840 created "2018-08-22" @default.
• W2885293840 creator A5023712733 @default.
• W2885293840 creator A5034008350 @default.
• W2885293840 creator A5082033474 @default.
• W2885293840 date "2018-01-01" @default.
• W2885293840 modified "2023-09-25" @default.
• W2885293840 title "The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis" @default.
• W2885293840 cites W1534401608 @default.
• W2885293840 cites W1969950242 @default.
• W2885293840 cites W2011582582 @default.
• W2885293840 cites W2060532763 @default.
• W2885293840 cites W2075894019 @default.
• W2885293840 cites W2096745115 @default.
• W2885293840 cites W2098499757 @default.
• W2885293840 cites W2114505219 @default.
• W2885293840 cites W2118605519 @default.
• W2885293840 cites W2122574381 @default.
• W2885293840 cites W2122929031 @default.
• W2885293840 cites W2127395702 @default.
• W2885293840 cites W2151262170 @default.
• W2885293840 cites W2153556154 @default.
• W2885293840 cites W2157250162 @default.
• W2885293840 cites W2164777416 @default.
• W2885293840 cites W2216283397 @default.
• W2885293840 cites W2275088062 @default.
• W2885293840 cites W2394773016 @default.
• W2885293840 cites W2472190236 @default.
• W2885293840 cites W2561439167 @default.
• W2885293840 cites W2607518013 @default.
• W2885293840 cites W2609430257 @default.
• W2885293840 cites W2780840759 @default.
• W2885293840 cites W2791139688 @default.
• W2885293840 cites W4231018668 @default.
• W2885293840 cites W4234081105 @default.
• W2885293840 doi "https://doi.org/10.1177/1178223418792250" @default.
• W2885293840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6077892" @default.
• W2885293840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30090017" @default.
• W2885293840 hasPublicationYear "2018" @default.
• W2885293840 type Work @default.
• W2885293840 sameAs 2885293840 @default.
• W2885293840 citedByCount "5" @default.
• W2885293840 countsByYear W28852938402019 @default.
• W2885293840 countsByYear W28852938402020 @default.
• W2885293840 countsByYear W28852938402021 @default.
• W2885293840 countsByYear W28852938402022 @default.
• W2885293840 crossrefType "journal-article" @default.
• W2885293840 hasAuthorship W2885293840A5023712733 @default.
• W2885293840 hasAuthorship W2885293840A5034008350 @default.
• W2885293840 hasAuthorship W2885293840A5082033474 @default.
• W2885293840 hasBestOaLocation W28852938401 @default.
• W2885293840 hasConcept C121608353 @default.
• W2885293840 hasConcept C126322002 @default.
• W2885293840 hasConcept C141071460 @default.
• W2885293840 hasConcept C143998085 @default.
• W2885293840 hasConcept C168563851 @default.
• W2885293840 hasConcept C2776694085 @default.
• W2885293840 hasConcept C2777802072 @default.
• W2885293840 hasConcept C2778292576 @default.
• W2885293840 hasConcept C2780110267 @default.
• W2885293840 hasConcept C2780140570 @default.
• W2885293840 hasConcept C2908647359 @default.
• W2885293840 hasConcept C31174226 @default.
• W2885293840 hasConcept C530470458 @default.
• W2885293840 hasConcept C71924100 @default.
• W2885293840 hasConcept C95190672 @default.
• W2885293840 hasConcept C99454951 @default.
• W2885293840 hasConceptScore W2885293840C121608353 @default.
• W2885293840 hasConceptScore W2885293840C126322002 @default.
• W2885293840 hasConceptScore W2885293840C141071460 @default.
• W2885293840 hasConceptScore W2885293840C143998085 @default.
• W2885293840 hasConceptScore W2885293840C168563851 @default.
• W2885293840 hasConceptScore W2885293840C2776694085 @default.
• W2885293840 hasConceptScore W2885293840C2777802072 @default.
• W2885293840 hasConceptScore W2885293840C2778292576 @default.
• W2885293840 hasConceptScore W2885293840C2780110267 @default.
• W2885293840 hasConceptScore W2885293840C2780140570 @default.
• W2885293840 hasConceptScore W2885293840C2908647359 @default.
• W2885293840 hasConceptScore W2885293840C31174226 @default.
• W2885293840 hasConceptScore W2885293840C530470458 @default.
• W2885293840 hasConceptScore W2885293840C71924100 @default.
• W2885293840 hasConceptScore W2885293840C95190672 @default.
• W2885293840 hasConceptScore W2885293840C99454951 @default.
• W2885293840 hasLocation W28852938401 @default.
• W2885293840 hasLocation W28852938402 @default.
• W2885293840 hasLocation W28852938403 @default.
• W2885293840 hasLocation W28852938404 @default.
• W2885293840 hasOpenAccess W2885293840 @default.
• W2885293840 hasPrimaryLocation W28852938401 @default.
• W2885293840 hasRelatedWork W1255356622 @default.
• W2885293840 hasRelatedWork W2013809648 @default.
• W2885293840 hasRelatedWork W2358701816 @default.
• W2885293840 hasRelatedWork W2367105124 @default.
• W2885293840 hasRelatedWork W2390548009 @default.
• W2885293840 hasRelatedWork W2534174115 @default.
• W2885293840 hasRelatedWork W2559834580 @default.
• W2885293840 hasRelatedWork W3089077900 @default.
• W2885293840 hasRelatedWork W3092055942 @default.

• next